Medication info
Sitagliptin 25 mg (Sitagliptin Hydrochloride Hydrate)

Sitagliptin 25 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.35mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink, round, biconvex film-coated tablet
Packaging
28 tablets/box [14 tablets/PTPX2]
Approval status
Active

MFDS item code 202101406 · Approved 2021.02.18 · Insurance code 657807930

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This drug is administered once daily at a dose of 100 mg as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used along with dietary therapy and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be used alone when starting drug therapy for the first time. If blood sugar control is difficult with monotherapy, it can be combined with metformin. Additionally, if blood sugar is insufficiently controlled with monotherapies such as sulfonylureas, metformin, thiazolidinediones, or insulin, this medication can be added. If blood sugar control remains inadequate with complex combination therapy, adding this medication may improve blood sugar control. Therefore, this medication effectively improves blood sugar control in patients with type 2 diabetes.

Dosage and Administration

Adult dosage

This drug is administered once daily at a dose of 100 mg as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Precautions

This medication may rarely cause serious allergic reactions after administration, so if symptoms such as skin rash or difficulty breathing occur, it should be discontinued immediately and a physician consulted. During the use of this medication, serious inflammation of the pancreas, known as pancreatitis, may arise. If symptoms such as abdominal pain, vomiting, or nausea appear, healthcare personnel should be informed immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients with allergies to this medication or its components. Patients with impaired kidney function should adjust the dosage of this medication; thus, kidney function tests should be performed before administration, and instructions from a physician should be followed. This medication may cause hypoglycemia when used alone or in combination with other diabetes treatments, so patients should be vigilant for symptoms of hypoglycemia and check blood sugar levels frequently if necessary. Severe joint pain or skin blisters may occur; if these symptoms arise, the medication should be stopped immediately and a physician consulted. Pregnant or breastfeeding women are advised not to use this medication, and safety in children and adolescents under 18 has not been established. Elderly patients should be monitored regularly for kidney function as it may decline when taking this medication. In case of overdose, general emergency treatment should be administered and hemodialysis considered if necessary; therefore, the prescribed dosage must be strictly followed. This medication has few significant drug interactions, but it is advisable to consult a physician or pharmacist when taking it with specific medications.

Side effects

anaphylaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air exposure, and it is best to keep it at a cool room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness for a longer time.

Appearance and packaging

Appearance

Pink, round, biconvex film-coated tablet

Package unit

28 tablets/box [14 tablets/PTPX2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.